However, the ability of Prkar1a reduction to resolve fasting hypoglycemia in the Sur1-/- hyperinsulinism model exposes new possible therapeutic targets in the liver, PKA and glucagon signaling pathways in the treatment of hyperinsulinemic hypoglycemia. This evidence concerns the gene GCG and Hypoglycemia.